VANCOUVER, BC, November 5th, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV)(FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is pleased to announce that it has been invited to and joined The Rapid Response Partnership Vehicle(RRPV), a consortium of large and small biopharma, contractors, government agencies, and academic and non-profit research institutions that support the USGovernment’s Biomedical Advanced Research and Development Authority (BARDA) inits objective to accelerate Medical Countermeasure product and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats.
The RRPV is a multiple-purpose acquisition vehicle to facilitate end-to-end development of future medical countermeasures, from the early stage through the advanced development, procurement, sustainment, and commercialization, including manufacturing infrastructure development. The RRPV is designed to foster and accelerate the speed of acquisition and partnerships in response to pandemics and other biothreat incidents and promotes innovation and rigorous development of medical countermeasures and enabling technologies to further enhance national health security.
A principal focus of the RRPV is to enable targeted product development expertise specifically for vaccines and therapeutics. Proposals are solicited from consortium members for individual project requirements on behalf of BARDA, which will evaluate proposals and authorizeRRPV to issue project agreements with Consortium members for individual projects.
The RRPV complements BARDA’s existing solicitation and acquisition vehicles such as theBroad Agency Announcement (BAA) and will expand the mechanisms through whichBARDA can rapidly partner with product developers in fields of interest toBARDA, such as improved flu vaccines and platform technologies that enable expedited turn-around for vaccine development.
BioVaxys President and Chief Operating Officer Kenneth Kovan says “We are pleased to join the RRPV consortium with organizations including Astra-Zeneca, Battelle, Deutsches Zentrum für Infektionsforschung e.V. (The German Center for Infection Research),Genentech, Ginkgo Bioworks, Inc., Novavax and Leidos. We believe DPX can play a major role in the development of BARDA’s priority vaccine programs, and having the ability to collaborate with such world-renowned consortium members will no doubt be a significant benefit for the Company.”
About BioVaxys Technology Corp.
BioVaxys Technology Corp.(www.biovaxys.com) is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX™immune-educating technology platform and its HapTenix© "neoantigen"tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S(MVP-S), based on the DPX™ platform, and is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly over expressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 Tcell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX-rPA for anthrax, DPX-flu for influenza, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© "neoantigen" tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB)and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Revolutionizing treatment delivery
